Compugen SVP exercises options and sells shares

Compugen Ltd senior vice president of business development Zurit Levine exercised options to acquire 1,875 Ordinary Shares at $0.8292 per share and, on the same date, sold 1,875 Ordinary Shares at $2.50 per share in an open-market transaction.

Rhea-AI Filing Summary

Compugen Ltd senior vice president of business development Zurit Levine exercised options to acquire 1,875 Ordinary Shares at $0.8292 per share and, on the same date, sold 1,875 Ordinary Shares at $2.50 per share in an open-market transaction. The trades were made pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Following these transactions, Levine directly holds 29,375 Ordinary Shares and 3,750 share options with a $0.8292 exercise price expiring on November 9, 2032.

Filing Explained

After the July 9 exercise-and-sale sequence, the filer directly holds 29,375 ordinary shares and retains 3,750 options.

The July 13, 2026 Form 4 reports that Zurit Levine, Compugen’s SVP of Business Development, exercised 1,875 options at $0.8292 and sold 1,875 ordinary shares at $2.5 on July 9, 2026; afterward, the filing shows 29,375 directly held ordinary shares and 3,750 options.

Form 4 code M identifies an option or derivative exercise, while code S identifies an open-market sale, so this filing describes an exercise followed by a share sale rather than a sale of the options themselves.

The filing states that the transactions were made under a Rule 10b5-1 plan adopted on December 23, 2025; that disclosure identifies the plan’s adoption date, not the reasons for these individual trades.

The remaining option disclosure states that 25% vested on December 31, 2023 and that the remainder vests in 12 equal quarterly installments, subject to continued service to Compugen.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,875 shares ($3K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Levine Zurit

Role SVP, Business Development

Sold 1,875 shs ($5K)

Approx. gross sale proceeds $5K

Approx. exercise cost $2K

Approx. pre-tax spread $3K

Type	Security	Shares	Price	Value
Exercise	Share Option (right to buy) F1, F2	1,875	$0.00	$0.00
Exercise	Ordinary Shares F1	1,875	$0.8292	$2K
Sale	Ordinary Shares F1	1,875	$2.50	$5K

Holdings After Transaction: Share Option (right to buy) — 3,750 contracts (Direct); Ordinary Shares — 29,375 shares (Direct)

Footnotes (2)

1. F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.
2. F2. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Shares sold: 1,875 Ordinary Shares Sale price: $2.50 per share Options exercised: 1,875 Ordinary Shares +3 more

6 metrics

Shares sold 1,875 Ordinary Shares Open-market sale on July 9, 2026 at $2.50 per share

Sale price $2.50 per share Price received for 1,875 Ordinary Shares sold on July 9, 2026

Options exercised 1,875 Ordinary Shares Shares acquired via option exercise on July 9, 2026

Exercise price $0.8292 per share Exercise price of options converted into 1,875 Ordinary Shares

Shares held after 29,375 Ordinary Shares Direct ownership after the reported transactions

Options remaining 3,750 share options Direct derivative holdings after exercise; strike $0.8292, expire November 9, 2032

Key Terms

Rule 10b5-1 trading plan, derivative security, Share Option (right to buy)

3 terms

Rule 10b5-1 trading plan financial

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Share Option (right to buy) financial

"security_title": "Share Option (right to buy)""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Compugen (CGEN) executive Zurit Levine report in this Form 4?

Zurit Levine reported exercising options for 1,875 Ordinary Shares at $0.8292 and selling 1,875 Ordinary Shares at $2.50 on July 9, 2026, in open-market transactions under a Rule 10b5-1 plan.

How many Compugen (CGEN) shares does Zurit Levine own after the reported transactions?

After the transactions, Zurit Levine directly holds 29,375 Ordinary Shares of Compugen and 3,750 share options with a $0.8292 exercise price expiring November 9, 2032.

At what prices did Zurit Levine trade Compugen (CGEN) stock in this filing?

Levine exercised options at $0.8292 per share and sold Ordinary Shares at $2.50 per share. The option exercise and share sale both involved 1,875 shares on July 9, 2026.

Were the Compugen (CGEN) trades by Zurit Levine under a Rule 10b5-1 plan?

Yes. A footnote states the share sale was made pursuant to a Rule 10b5-1 trading plan adopted by Zurit Levine on December 23, 2025, indicating the trade was pre-arranged.

What options does Zurit Levine still hold in Compugen (CGEN)?

Levine holds 3,750 share options with a $0.8292 exercise price, expiring on November 9, 2032. The options vested 25% on December 31, 2023, with the remainder in 12 equal quarterly installments.

What role does Zurit Levine hold at Compugen (CGEN)?

Zurit Levine is an officer of Compugen, serving as Senior Vice President, Business Development, according to the insider information disclosed alongside the reported transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levine Zurit

(Last) (First) (Middle)

C/O COMPUGEN LTD.

26 HAROKMIM STREET

(Street)

HOLON 5885849

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Business Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/09/2026		M(1)		1,875	A	$0.8292	31,250	D
Ordinary Shares	07/09/2026		S(1)		1,875	D	$2.5	29,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$0.8292	07/09/2026		M(1)			1,875	(2)	11/09/2032	Ordinary Shares	1,875	$0	3,750	D

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.

2. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ Zurit Levine	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)